Top line stable.
+4.0% YoY versus +2.2% prior. 3y CAGR +0.9%.
+4.0%We use cookies
MainRatios uses cookies for essential site functions. With your consent, we also use analytics cookies including session replay sampling (PostHog, Google Analytics) and advertising cookies (Google AdSense). You can reject non-essential cookies, including the "sale" or sharing of personal information under CCPA, and you may withdraw consent at any time (GDPR). See our Privacy Policy for details.
Healthcare · Market Cap: $22.9B
Fundamentals as of 2026-03-31
All analysis on this page is for educational purposes only and does not constitute financial advice. Fair values are model-based estimates. Always do your own research.
The Question
Bottom line: MTD currently has no legendary investor models qualifying — see /stock/MTD/valuation for the per-model breakdown, but earns a D sector grade (42/100) in Healthcare. Use the per-tab analysis to form your own view. Drill into the valuation breakdown and sector ranking for the full picture.
Mettler-Toledo International Inc.'s ROE and debt-to-equity are non-meaningful — large accumulated buybacks have driven stockholders' equity below zero, so the ratio denominators are uninterpretable. Operating margin and free cash flow are the better lenses here.
Financial story
Mettler-Toledo International Inc.'s ROE and debt-to-equity are non-meaningful — large accumulated buybacks have driven stockholders' equity below zero, so the ratio denominators are uninterpretable. Operating margin and free cash flow are the better lenses here.
MTD's earnings calendar and history are tracked in the financials tab. Specific dates depend on company-published guidance.
MTD is in the Healthcare sector. Sector ranking and peer comparison are in the sector tab.
0 of 6 legendary investor models rate MTD a BUY. Fair value estimates and full investor breakdown are in the valuation tab.
Mettler-Toledo International Inc.'s fair value depends on which model you trust. See the per-investor fair-value table in the valuation tab.
MTD trades at 26.3x earnings. Sector context and per-investor signals are in the valuation tab.
MTD and LH differ on P/E, ROE, and revenue growth. See the full MTD vs LH compare matrix.
How does MTD compare?
+4.0% YoY versus +2.2% prior. 3y CAGR +0.9%.
+4.0%Net margin 21.6% versus 22.3% prior (−0.7pp). Operating 27.8%.
21.6%P/E 27.0x — 19% below the 5y median of 33.2x. Forward 24.5x hints at EPS expansion next year.
27.0xSee exactly where MTD ranks
Sign in to unlock the full sector ranking — free.
Sign in to see the rankingMTD sits at #84 in Healthcare with a D grade (42/100).